Evidence map›Paper›PMID 28526722›Full record

Trial reportThe oncologist2017

Phase II Study of Modified Carboplatin Plus Weekly Nab-Paclitaxel in Elderly Patients with Non-Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1301.

Eisaku Miyauchi, Akira Inoue, Kazuhiro Usui, Shunichi Sugawara, Makoto Maemondo, Heisuke Saito, Yuka Fujita, Terufumi Kato, Toshiro Suzuki, Toshiyuki Harada and 3 more

Open access · bronzeAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The oncologist, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 16 citations in OpenAlex.

  1. Trial
  2. The effect of nabilone on appetite, nutritional status, and quality of life in lung cancer patients: a randomized, double-blind clinical trial.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2018
    Trial
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 11 institutions in 2 countries.

Eisaku MiyauchiDepartment of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan miyauchi@rm.med.tohoku.ac.jp.
Akira InoueDepartment of Palliative Medicine, Tohoku University School of Medicine, Senadi, Japan.
Kazuhiro UsuiDivision of Respirology, NTT Medical Center Tokyo, Tokyo, Japan.
Shunichi SugawaraDepartment of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan.
Makoto MaemondoDepartment of Respiratory Medicine, Miyagi Cancer Center, Natori, Japan.
Heisuke SaitoDepartment of Respiratory Medicine, Iwate Medical University Hospital, Morioka, Japan.
Yuka FujitaDepartment of Respiratory Medicine, Asahikawa Medical Center, Asahikawa, Japan.
Terufumi KatoDepartment of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan.
Toshiro SuzukiDepartment of Respiratory Medicine, Isawa Hospital, Fuefuki, Japan.
Toshiyuki HaradaCenter for Respiratory Diseases, JCHO Hokkaido Hospital, Sapporo, Japan.
Hiroshi WatanabeDepartment of Respiratory Medicine, Saka General Hospital, Shiogama, Japan.
Taku NakagawaThoracic Surgery, Omagari-Kosei Medical Center, Daisen, Japan.
Masakazu IchinoseDepartment of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.
Tohoku University · JPAsahikawa Medical University · JPFuchu Hospital · JPGeneral Hospital of Drama · GRHokkaido hospital · JPIwate Medical University · JPKanagawa Cardiovascular and Respiratory Center · JPMisasa Onsen Hospital · JPMiyagi Prefectural Hospital Organization · JPNTT Medical Center · JPSendai Kousei Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

lessons learnedWeekly nanoparticle albumin-bound-paclitaxel (75 mg/m

backgroundThe CA031 trial suggested weekly nanoparticle albumin-bound-paclitaxel (nab-PTX) was superior in efficacy to paclitaxel (PTX) once every 3 weeks when combined with carboplatin (CBDCA) for advanced non-small cell lung cancer (NSCLC) patients; a subgroup analysis of elderly patients looked promising. In a multicenter phase II trial, we prospectively evaluated the efficacy and tolerability of modified CBDCA plus weekly nab-PTX for elderly patients with untreated advanced NSCLC.

methodsEligible patients received CBDCA (area under the curve [AUC] 6 mg/mL/min) on day 1 and nab-PTX (75 mg/m

resultsOf 32 patients (median age of 78 years), 84% were male, 56% had stage IV NSCLC, and 56% had squamous cell carcinoma. ORR and disease control rates were 50% (95% confidence interval (CI): 33-67) and 94% (95% CI: 85-100), respectively. Median PFS and OS were 6.4 months (95% CI: 4.8-8.0) and 17.5 months (95% CI: 11.9-23.1), respectively. Grade ≥3 toxicities were neutropenia (47%), leukopenia (38%), anemia (34%), thrombocytopenia (25%), and anorexia (9%). Febrile neutropenia and treatment-related deaths were not observed.

conclusionModified CBDCA plus weekly nab-PTX demonstrated significant efficacy and acceptable toxicities in elderly patients with advanced NSCLC.

Indexed as

AgedAged, 80 and overAlbuminsAntineoplastic Combined Chemotherapy ProtocolsCarboplatinCarcinoma, Non-Small-Cell LungDisease-Free SurvivalDrug-Related Side Effects and Adverse ReactionsFemaleHumansJapanMalePaclitaxelTreatment Outcome130-nm albumin-bound paclitaxelAlbuminsCarboplatinPaclitaxel

Identifiers

PMID28526722
PMCPMC5469596
OpenAlexW2616578228

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.